Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited am...

Descripción completa

Detalles Bibliográficos
Autores principales: Gertz, Morie A., Cohen, Adam D., Comenzo, Raymond L., Kastritis, Efstathios, Landau, Heather J., Libby, Edward N., Liedtke, Michaela, Sanchorawala, Vaishali, Schönland, Stefan, Wechalekar, Ashutosh, Zonder, Jeffrey A., Palladini, Giovanni, Walling, Jackie, Guthrie, Spencer, Nie, Christie, Karp, Carol, Jin, Yuying, Kinney, Gene G., Merlini, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644097/
https://www.ncbi.nlm.nih.gov/pubmed/37366170
http://dx.doi.org/10.1182/blood.2022019406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644097/
https://www.ncbi.nlm.nih.gov/pubmed/37366170
http://dx.doi.org/10.1182/blood.2022019406

Ejemplares similares